Greg Friese via Flickr
Heather Bresch, the CEO of Mylan — which makes the EpiPen — is testifying in front of the House Oversight and Government Reform Committee Wednesday afternoon at 2 p.m. about the drug's price, though the hearing has been delayed as the House votes.
The price device, used in emergencies to treat severe allergic reactions, has increased more than 500% since Mylan acquired it in 2007. A two-pack of the EpiPen now has a list price of $608.
In her prepared testimony released ahead of the hearing, Bresch gave a background on Mylan as a company, and addressed some of the controversy around the rising price.
"Looking back, I wish we had better anticipated the magnitude and acceleration of the rising financial issues for a growing minority of patients who may have ended up paying the full [list] price or more," Bresch said in her testimony. "We never intended this."
You can watch the whole thing live here.
The congressmen are going to have a lot of questions for Bresch, who will be testifying alongside FDA deputy director Dr. Doug Throckmorton. In her defense, she says the company is implementing a number of programs to help patients pay for EpiPens.
NOW WATCH: KRUGMAN: Free markets won't solve the problem driving EpiPen prices higher
See Also:
- Here's what to expect when the CEO of EpiPen-maker Mylan testifies before Congress
- The EpiPen pricing scandal just got even more complicated for the CEO and her family at the heart of it
- Jimmy Kimmel made a hilarious jab at the skyrocketing price of EpiPens while handing out PB&Js at the Emmys
SEE ALSO: 2 questions EpiPen's maker desperately wants America to forget while it faces Congress
DON'T MISS: These companies you've never heard of are about to incite another massive drug price outrage
